Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer

Clinical Cancer Research

Volumn 17, Issue 13, 2011, Pages 4531-4540

  Tanaka, Motofumi ^a   Chang, Ping ^a   Li, Yanan ^a   Li, Donghui ^a   Overman, Michael ^a   Maru, Dipen M ^a   Sethi, Salil ^a   Phillips, Jonathan ^a   Bland, Gail L ^a   Abbruzzese, James L ^a   Eng, Cathy ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CHFR GENE; COLON CANCER; CONTROLLED STUDY; CPG ISLAND; DISEASE FREE SURVIVAL; DNA METHYLATION; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; ID4 GENE; MAJOR CLINICAL STUDY; MALE; MINT1 GENE; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; RECEIVER OPERATING CHARACTERISTIC; RECK GENE; RECURRENT DISEASE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; COLONIC NEOPLASMS; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 79960311900     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0763     Document Type: Article

References (51)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA. Cancer J Clin 2010;60:277-300.
2. Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009;27:872-7.
3. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370:2020-9.
4. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer prognostic factors consensus conference: Colorectal Working Group. Cancer 2000;88:1739-57. (Pubitemid 30183160)
5. Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003;21:2912-9. (Pubitemid 46621841)
6. Krasna MJ, Flancbaum L, Cody RP, Shneibaum S, Ben Ari G. Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance. Cancer 1988;61:1018-23.
7. Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408-19. (Pubitemid 41103700)
8. Samantas E, Dervenis C, Rigatos SK. Adjuvant chemotherapy for colon cancer: evidence on improvement in survival. Dig Dis 2007;25:67-75. (Pubitemid 46478244)
9. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011;29:11-6.
10. Alberts SR, Sinicrope FA, Grothey A. N0147. A randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer. Clin Colorectal Cancer 2005;5:211-3.
11. De Gramont A, Cutsem EV, Tabernero J, Moore MJ, Cunningham D, Rivera F, et al. AVANT: Results from a randomized, three-arm multi-national phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. J Clin Oncol 2011;29(suppl 4):362[abstract].
12. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet 2010;375:1030-47.
13. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009;9:489-99.
14. Chua W, Moore MM, Charles KA, Clarke SJ. Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. Curr Opin Mol Ther 2009;11:611-22.
15. Lurje G, Zhang W, Lenz HJ. Molecular prognostic markers in locally advanced colon cancer. Clin Colorectal Cancer 2007;6:683-90. (Pubitemid 350221365)
16. Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H, Ajani JA. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. Cancer 2009;115:3609-17.
17. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92. (Pubitemid 46273572)
18. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59.
19. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143-53. (Pubitemid 38198742)
20. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008;135:1079-99.
21. Shen L, Catalano PJ, Benson AB 3rd, O'Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 2007;13:6093-8. (Pubitemid 350075067)
22. Umetani N, Takeuchi H, Fujimoto A, Shinozaki M, Bilchik AJ, Hoon DS. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin Cancer Res 2004;10:7475-83. (Pubitemid 39557508)
23. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-6.
24. Toyota M, Sasaki Y, Satoh A, Ogi K, Kikuchi T, Suzuki H, et al. Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci U S A 2003;100:7818-23. (Pubitemid 36760053)
25. Noetzel E, Veeck J, Niederacher D, Galm O, Horn F, Hartmann A, et al. Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer 2008;8:154.
26. Cho CY, Wang JH, Chang HC, Chang CK, Hung WC. Epigenetic inactivation of the metastasis suppressor RECK enhances invasion of human colon cancer cells. J Cell Physiol 2007;213:65-9.
27. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe-Toyota M, et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999;59:2307-12. (Pubitemid 29242273)
28. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003;35:146-50. (Pubitemid 36828724)
29. Shen L, Guo Y, Chen X, Ahmed S, Issa JP. Optimizing annealing temperature overcomes bias in bisulfite PCR methylation analysis. Biotechniques 2007;42:48,50, 52 passim.
30. Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials 2000;21:552-60. (Pubitemid 32056218)
31. Allegra C, Sargent DJ. Adjuvant therapy for colon cancer - the pace quickens. N Engl J Med 2005;352:2746-8. (Pubitemid 41007831)
32. Scolnick DM, Halazonetis TD. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 2000;406:430-5. (Pubitemid 30625565)
33. Satoh A, Toyota M, Itoh F, Sasaki H, Ogi K, Kikuchi T, et al. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 2003;63:8606-13. (Pubitemid 38064034)
34. Mizuno K, Osada H, Konishi H, Tatematsu Y, Yatabe Y, Mitsudomi T, et al. Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene 2002;21:2328-33. (Pubitemid 34407292)
35. Baba S, Hara A, Kato K, Long NK, Hatano Y, Kimura M, et al. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas. Oncol Rep 2009;22:1173-9.
36. Yu X, Minter-Dykhouse K, Malureanu L, Zhao WM, Zhang D, Merkle CJ, et al. Chfr is required for tumor suppression and Aurora A regulation. Nat Genet 2005;37:401-6.
37. Privette LM, Gonzalez ME, Ding L, Kleer CG, Petty EM. Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression. Cancer Res 2007;67:6064-74. (Pubitemid 47037485)
38. Fukuda T, Kondo Y, Nakagama H. The anti-proliferative effects of the CHFR depend on the forkhead associated domain, but not E3 ligase activity mediated by ring finger domain. PLoS One 2008;3:e1776.
39. Kashima L, Toyota M, Mita H, Suzuki H, Idogawa M, Ogi K, et al. CHFR, a potential tumor suppressor, downregulates interleukin-8 through the inhibition of NF-kappaB. Oncogene 2009;28:2643-53.
40. Oh YM, Kwon YE, Kim JM, Bae SJ, Lee BK, Yoo SJ, et al. Chfr is linked to tumour metastasis through the downregulation of HDAC1. Nat Cell Biol 2009;11:295-302.
41. Brandes JC, van Engeland M, Wouters KA, Weijinberg MP, Herman JG. CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis 2005;26:1152-6. (Pubitemid 41214309)
42. Fu Z, Regan K, Zhang L, Muders MH, Thibodeau SN, French A, et al. Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice. J Clin Invest 2009;119:2714-24.
43. Gryfe R, Kim H, Hsieh E, Aronson M, Holowaty E, Bull S, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000;342:69-77. (Pubitemid 30036597)
44. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28:3219-26.
45. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57. (Pubitemid 36859476)
46. Toyota M, Ohe-Toyota M, Ahuja N, Issa JP. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A 2000;97:710-5. (Pubitemid 30070374)
47. Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008;3:e3698.
48. Deng G, Kakar S, Tanaka H, Matsuzaki K, Miura S, Sleisenger MH, et al. Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics. Eur J Cancer 2008;44:1290-301.
49. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 2008;100:1734-8.
50. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 2009;101:124-31.
51. Valentini AM, Armentano R, Pirrelli M, Caruso ML. Chemotherapeutic agents for colorectal cancer with a defective mismatch repair system: the state of the art. Cancer Treat Rev 2006;32:607-18. (Pubitemid 44649135)